Fulgent Genetics Revenue Tops Estimates @themotleyfool #stocks $FLGT

Fulgent Genetics Revenue Tops Estimates @themotleyfool #stocks $FLGT

Laboratory services and therapeutic development specialist Fulgent Genetics (NASDAQ:FLGT) delivered a standout performance in the fourth quarter, topping analysts' consensus estimates. On Friday, Feb. 28, the company reported adjusted EPS of $0.04, outstripping expectations of a $0.12 per-share loss. Q4 revenue climbed to $76.2 million, exceeding estimates of $74 million, marking an impressive annual growth of 8.1%. Despite a GAAP earnings loss,…

Fulgent Genetics Inc Q4 2024 Earnings: EPS Loss of ($0.19) Beats Estimate, Revenue at $76. …

On February 28, 2025, Fulgent Genetics Inc (FLGT, Financial) released its 8-K filing detailing the financial results for the fourth quarter and full year ending December 31, 2024. Fulgent Genetics Inc, a technology company specializing in genetic testing and therapeutic development, reported a total revenue of $76.2 million for Q4 2024, slightly surpassing the analyst estimate of $76.09 million. However, the company reported a GAAP loss of $5.9 …